Tositumomab (original) (raw)
Le tositumomab est anticorps monoclonal murin IgG2a anti‑CD20 conjugué à l'iode 131. L'action thérapeutique résulte de la capacité de ciblage de l'anticorps monoclonal associée à l'effet antitumoral des radiations dues au radionucléide, essentiellement par émission de particules α. Il est ainsi commercialisé sous le nom de Bexxar.
| Property | Value |
|---|---|
| dbo:abstract | Le tositumomab est anticorps monoclonal murin IgG2a anti‑CD20 conjugué à l'iode 131. L'action thérapeutique résulte de la capacité de ciblage de l'anticorps monoclonal associée à l'effet antitumoral des radiations dues au radionucléide, essentiellement par émission de particules α. Il est ainsi commercialisé sous le nom de Bexxar. (fr) Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. It is classified as a IgG2a lambda antibody. The drug combination was developed by Corixa which was purchased by GlaxoSmithKline in 2005. It was sold for about $25,000 for one round of treatment. Bexxar competed with Zevalin, until the former's discontinuation in 2014. (en) Il tositumomab, nome commerciale Bexxar è un anticorpo monoclonale usato nel trattamento del linfoma follicolare; esso è un anticorpo antiIgG2a anti , derivato da di topo. Il farmaco è usato, legato covalentemente con lo iodio radionuclide, in infusione sequenziale iodio (131I)tositumomab, Lo 131I emette radiazioni beta e gamma e decade con un'emivita di 8 giorni. Studi clinici hanno stabilito l'efficacia del farmaco nel linfoma follicolare in regimi di chemioterapia refrattari al rituximab. Viene prodotto da ora GlaxoSmithKline. Alcuni studi indicherebbemo una minore piastrinopenia rispetto all'ibritumomab tiuxetan. (it) |
| dbo:alternativeName | Bexxar (en) |
| dbo:atcCode | (sequential regimen with 131I form) |
| dbo:casNumber | 208921-02-2 |
| dbo:chEMBL | 1201604 |
| dbo:drugbank | DB00081 |
| dbo:fdaUniiCode | 0343IGH41U |
| dbo:kegg | D08622 |
| dbo:medlinePlus | a609013 |
| dbo:wikiPageID | 6609238 (xsd:integer) |
| dbo:wikiPageLength | 8534 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1102283844 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Non-Hodgkins_lymphoma dbr:Unsealed_source_radiotherapy dbr:Iodine-131 dbc:GSK_plc_brands dbr:Corixa_(company) dbr:Radiopharmaceutical dbr:GlaxoSmithKline dbr:Monoclonal_antibody dbr:Murine dbr:Clinical_trial dbr:Gamma_camera dbr:Amersham_plc dbr:European_Medicines_Agency dbr:FDA dbr:Follicular_lymphoma dbr:Non-Hodgkin_lymphoma dbr:Refractory dbc:Monoclonal_antibodies dbr:Chemotherapy dbr:Biologics_license_application dbr:IgG dbr:Zevalin dbr:CD20 dbr:Oncologist dbr:Investigational_new_drug dbr:Rituxan dbr:Orphan_drug_status dbr:Covalently_bonded |
| dbp:atcPrefix | V10 (en) |
| dbp:atcSuffix | XA53 (en) |
| dbp:atcSupplemental | (en) |
| dbp:c | 6416 (xsd:integer) |
| dbp:casNumber | 208921 (xsd:integer) |
| dbp:chembl | 1201604 (xsd:integer) |
| dbp:chemspiderid | none (en) |
| dbp:drugbank | DB00081 (en) |
| dbp:h | 9874 (xsd:integer) |
| dbp:kegg | D08622 (en) |
| dbp:mabType | mab (en) |
| dbp:medlineplus | a609013 (en) |
| dbp:n | 1688 (xsd:integer) |
| dbp:o | 1987 (xsd:integer) |
| dbp:s | 44 (xsd:integer) |
| dbp:source | o (en) |
| dbp:target | dbr:CD20 |
| dbp:tradename | Bexxar (en) |
| dbp:type | mab (en) |
| dbp:unii | 343 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 470611959 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Reflist dbt:Rp dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Drugs.com dbt:Extracellular_chemotherapeutic_agents dbt:Therapeutic_radiopharmaceuticals dbt:Monoclonals_for_tumors |
| dcterms:subject | dbc:GSK_plc_brands dbc:Monoclonal_antibodies |
| gold:hypernym | dbr:IgG |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 |
| rdfs:comment | Le tositumomab est anticorps monoclonal murin IgG2a anti‑CD20 conjugué à l'iode 131. L'action thérapeutique résulte de la capacité de ciblage de l'anticorps monoclonal associée à l'effet antitumoral des radiations dues au radionucléide, essentiellement par émission de particules α. Il est ainsi commercialisé sous le nom de Bexxar. (fr) Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. It is classified as a IgG2a lambda antibody. The drug combination was developed by Corixa which was purchased by GlaxoSmithKline in 2005. It was sold for about $25,000 for one round of treatment. Bexxar competed with Zevalin, until the former's discontinuation in 2014. (en) Il tositumomab, nome commerciale Bexxar è un anticorpo monoclonale usato nel trattamento del linfoma follicolare; esso è un anticorpo antiIgG2a anti , derivato da di topo. Il farmaco è usato, legato covalentemente con lo iodio radionuclide, in infusione sequenziale iodio (131I)tositumomab, Lo 131I emette radiazioni beta e gamma e decade con un'emivita di 8 giorni. Studi clinici hanno stabilito l'efficacia del farmaco nel linfoma follicolare in regimi di chemioterapia refrattari al rituximab. Viene prodotto da ora GlaxoSmithKline. (it) |
| rdfs:label | Tositumomab (it) Tositumomab (fr) Tositumomab (en) |
| owl:sameAs | freebase:Tositumomab yago-res:Tositumomab http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00081 wikidata:Tositumomab dbpedia-fr:Tositumomab dbpedia-it:Tositumomab dbpedia-sh:Tositumomab dbpedia-sr:Tositumomab https://global.dbpedia.org/id/3hJXt |
| prov:wasDerivedFrom | wikipedia-en:Tositumomab?oldid=1102283844&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Tositumomab |
| is dbo:wikiPageRedirects of | dbr:Bexxar dbr:Bexxar_regimen dbr:ATC_code_V10XA53 dbr:ATCvet_code_QV10XA53 dbr:Iodine_(131I)_tositumomab dbr:Iodine_I_131_tositumomab dbr:Iodine_i_131_tositumomab |
| is dbo:wikiPageWikiLink of | dbr:List_of_antineoplastic_agents dbr:Primary_cutaneous_diffuse_large_B-cell_lymphoma,_leg_type dbr:Index_of_oncology_articles dbr:Nuclear_medicine_physician dbr:Bexxar dbr:Bexxar_regimen dbr:Monoclonal_antibody_therapy dbr:Nuclear_medicine dbr:Germinal_center_B-cell_like_diffuse_large_B-cell_lymphoma dbr:ATC_code_V10XA53 dbr:ATCvet_code_QV10XA53 dbr:Hairy_cell_leukemia dbr:ATC_code_V10 dbr:C6416H9874N1688O1987S44 dbr:CD20 dbr:Ibritumomab_tiuxetan dbr:Radiation_therapy dbr:Radioimmunotherapy dbr:List_of_therapeutic_monoclonal_antibodies dbr:Iodine_(131I)_tositumomab dbr:Iodine_I_131_tositumomab dbr:Iodine_i_131_tositumomab dbr:Personalized_medicine dbr:List_of_drugs:_Tj–Tq |
| is foaf:primaryTopic of | wikipedia-en:Tositumomab |